LRRK2 Pathways Leading to Neurodegeneration

Overview

Journal Curr Neurol Neurosci Rep

Specialty Neurology

Date 2015 May 27

PMID 26008812

Citations 75

Authors

Mark R Cookson

Affiliations

Soon will be listed here.

Abstract

Mutations in LRRK2 are associated with inherited Parkinson's disease (PD) in a large number of families, and the genetic locus containing the LRRK2 gene contains a risk factor for sporadic PD. The LRRK2 protein contains several domains that suggest a role in cellular signaling, including a kinase domain. It is also clear that LRRK2 interacts, either physically or genetically, with several other important proteins implicated in PD, suggesting that LRRK2 may be a central player in the pathways that underlie parkinsonism. As such, LRRK2 has been proposed to be a plausible target for therapeutic intervention, with kinase inhibition being pursued most actively. However, there are still several fundamental aspects of LRRK2 biology and function that remain unresolved at this time. This review will focus on the key questions of normal function of LRRK2 and how this might be related to the pathophysiology of PD.

Citing Articles

CalDAG-GEFI acts as a guanine nucleotide exchange factor for LRRK2 to regulate LRRK2 function and neurodegeneration.

Liu Q, Huang B, Guiberson N, Chen S, Zhu D, Ma G Sci Adv. 2024; 10(47):eadn5417.

PMID: 39576856 PMC: 11584015. DOI: 10.1126/sciadv.adn5417.

Primary cilia in Parkinson's disease: summative roles in signaling pathways, genes, defective mitochondrial function, and substantia nigra dopaminergic neurons.

Tian Z, Zhang Y, Xu J, Yang Q, Hu D, Feng J Front Aging Neurosci. 2024; 16:1451655.

PMID: 39364348 PMC: 11447156. DOI: 10.3389/fnagi.2024.1451655.

The Brain-Gut Axis, an Important Player in Alzheimer and Parkinson Disease: A Narrative Review.

Caradonna E, Nemni R, Bifone A, Gandolfo P, Costantino L, Giordano L J Clin Med. 2024; 13(14).

PMID: 39064171 PMC: 11278248. DOI: 10.3390/jcm13144130.

Emerging perspectives on precision therapy for Parkinson's disease: multidimensional evidence leading to a new breakthrough in personalized medicine.

Wang Q, Gu X, Yang L, Jiang Y, Zhang J, He J Front Aging Neurosci. 2024; 16:1417515.

PMID: 39026991 PMC: 11254646. DOI: 10.3389/fnagi.2024.1417515.

Dysregulated Wnt and NFAT signaling in a Parkinson's disease LRRK2 G2019S knock-in model.

Wetzel A, Lei S, Liu T, Hughes M, Peng Y, McKay T Sci Rep. 2024; 14(1):12393.

PMID: 38811759 PMC: 11137013. DOI: 10.1038/s41598-024-63130-8.

References

Zerial M, McBride H . Rab proteins as membrane organizers. Nat Rev Mol Cell Biol. 2001; 2(2):107-17. DOI: 10.1038/35052055. View

Helip-Wooley A, Thoene J . Sucrose-induced vacuolation results in increased expression of cholesterol biosynthesis and lysosomal genes. Exp Cell Res. 2004; 292(1):89-100. DOI: 10.1016/j.yexcr.2003.09.003. View

Marin I, van Egmond W, van Haastert P . The Roco protein family: a functional perspective. FASEB J. 2008; 22(9):3103-10. DOI: 10.1096/fj.08-111310. View

Eisenberg E, Greene L . Multiple roles of auxilin and hsc70 in clathrin-mediated endocytosis. Traffic. 2007; 8(6):640-6. DOI: 10.1111/j.1600-0854.2007.00568.x. View

Lee B, Shin J, VanKampen J, Petrucelli L, West A, Ko H . Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med. 2010; 16(9):998-1000. PMC: 2935926. DOI: 10.1038/nm.2199. View

Herzig M, Kolly C, Persohn E, Theil D, Schweizer T, Hafner T . LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet. 2011; 20(21):4209-23. PMC: 3188995. DOI: 10.1093/hmg/ddr348. View

Rudenko I, Chia R, Cookson M . Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?. BMC Med. 2012; 10:20. PMC: 3308210. DOI: 10.1186/1741-7015-10-20. View

Greggio E, Cookson M . Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro. 2009; 1(1). PMC: 2695577. DOI: 10.1042/AN20090007. View

Civiero L, Vancraenenbroeck R, Belluzzi E, Beilina A, Lobbestael E, Reyniers L . Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS One. 2012; 7(8):e43472. PMC: 3430690. DOI: 10.1371/journal.pone.0043472. View

10.

Stafa K, Trancikova A, Webber P, Glauser L, West A, Moore D . GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet. 2012; 8(2):e1002526. PMC: 3280333. DOI: 10.1371/journal.pgen.1002526. View

11.

Kay D, Kramer P, Higgins D, Zabetian C, Payami H . Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Mov Disord. 2005; 20(8):1077-8. DOI: 10.1002/mds.20618. View

12.

Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q . Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol. 2011; 7(4):203-5. PMC: 3287420. DOI: 10.1038/nchembio.538. View

13.

Henderson J, Kormos B, Hayward M, Coffman K, Jasti J, Kurumbail R . Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2014; 58(1):419-32. DOI: 10.1021/jm5014055. View

14.

Lewis P, Greggio E, Beilina A, Jain S, Baker A, Cookson M . The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun. 2007; 357(3):668-71. PMC: 1939973. DOI: 10.1016/j.bbrc.2007.04.006. View

15.

Skibinski G, Nakamura K, Cookson M, Finkbeiner S . Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J Neurosci. 2014; 34(2):418-33. PMC: 3870929. DOI: 10.1523/JNEUROSCI.2712-13.2014. View

16.

Zhang C, Engqvist-Goldstein A, Carreno S, Owen D, Smythe E, Drubin D . Multiple roles for cyclin G-associated kinase in clathrin-mediated sorting events. Traffic. 2005; 6(12):1103-13. DOI: 10.1111/j.1600-0854.2005.00346.x. View

17.

Manzoni C, Mamais A, Dihanich S, Abeti R, Soutar M, Plun-Favreau H . Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim Biophys Acta. 2013; 1833(12):2900-2910. PMC: 3898616. DOI: 10.1016/j.bbamcr.2013.07.020. View

18.

Law B, Spain V, Leinster V, Chia R, Beilina A, Cho H . A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation. J Biol Chem. 2013; 289(2):895-908. PMC: 3887213. DOI: 10.1074/jbc.M113.507913. View

19.

Beilina A, Rudenko I, Kaganovich A, Civiero L, Chau H, Kalia S . Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A. 2014; 111(7):2626-31. PMC: 3932908. DOI: 10.1073/pnas.1318306111. View

20.

Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans J, Daniels V . The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem. 2008; 283(24):16906-14. PMC: 2423262. DOI: 10.1074/jbc.M708718200. View